Hello, and welcome to Essity's conference announcing our interim report for the first quarter 2022. I am Joséphine Edwall, Senior Vice President, Essity Communications. Today our CEO will go through the highlights in the report. After Magnus Groth is finished with that, we will have a Q&A session together with our CFO, Fredrik Rystedt. With that, I hand over to you, Magnus.
Thank you, Joséphine, and welcome to this presentation of Essity's interim report for the first quarter 2022. To summarize and give some highlights, in the quarter, we saw significant price increases, helping our growth and our margins, and we are also seeing additional pricing coming in the coming quarters and preparing for further price increases throughout the year and into next year. Cost inflation has only increased since the last quarter, and of course, we have the war in Ukraine that's significantly impacting, especially energy, in Europe, but generally. We also see additional cost inflation in raw materials, transports, so in every area. We continue with a high pace of acquisitions, and in the first quarter, we acquired a U.S. professional wiping and cleaning company, Legacy Converting. We have also started work to exit Russia.
With all this going on, we continue to strengthen our core brands and our strong market positions with a high pace of innovations. We see this in continued strong market share development and online sales development, and also continue to stay as the leader in sustainability. Some more details on Russia, which accounts for approximately 2% of group sales or SEK 2.8 billion. In the country, we have three production facilities, 1,300 employees. We're taking an impairment of SEK 1.24 billion, but we keep a remaining SEK 1.3 billion in trade receivables, inventories, cash, and cash equivalents. The plants are operating, the business is continuing, our employees will continue to be employed.
We are looking at options to exit Russia, and of course, we have as a priority that our employees are well taken care of in this process. With that, I would like to move over to the financials. Q1 net sales increased with 24.6%. Of course, there's a big positive currency impact there. When looking at the sales growth, 14.6% organic, about half from volume and half from price and mix, so very, very good growth. I think this shows how quickly we have been coming out of, as we've been coming out of lockdowns and restrictions, which was very much in place during the first quarter last year, how quickly our different categories have recovered.
We also see here a significant contribution from the acquisitions that we've done over the last year. Including acquisitions, the growth was 17.3%. The severe impact from costs reduced adjusted EBITA with 22% and adjusted EBITA margin ended up at 8.2%. Operating cash flow from this perspective was strong, and the lower adjusted EBITA was compensated for with a strong working capital development, so similar operating cash flow as last year. This has been a very dynamic quarter in many ways.
Of course, the Russian invasion of Ukraine is impacting not only our business locally in these countries where, especially in Ukraine and in Russia, we are focusing on the health and safety of our employees, but also a big impact in Europe and also globally. As we can see from this waterfall, compared to a year ago, raw materials, energy, and distribution basically has a negative impact that is equal more or less the margin we had last year. Massive. We've never seen anything like this before. Typically, we talk about cost increases of a few percentage points at the most. Having said that, we have been able to compensate for a large part of that with higher prices, volumes, mix, cost savings, and other activities.
When it comes to the cost savings, they were SEK 34 million. Remember that we are very hard on ourselves when we calculate cost savings in cost of goods sold, so we only look at net inflation. Since we have very high inflation like everywhere else in the business, we think that this is a good number. We also see good underlying momentum in everything from material rationalization to higher rebates and efficiency improvements in other ways. That work is continuing. We have high capacity utilization in most of our production assets, which also helps, of course, from a cost perspective. A&P was slightly lower compared to last year, and then of course, also lower as in relation to sales. SG&A was higher, but lower in relation to sales.
We have never seen a bridge like this, and this is of course the reason why we have been talking so much about the need for price increases to compensate. What I think this shows is that we will be able to compensate for raw material, energy, and distribution cost headwinds also this time. Of course, since they continue and because of the extent of them, it takes some time. Moving over to innovations, this is something where we are continuing to invest to strengthen our brands and our market shares.
After the first quarter, we continued to remain very strong in our positions, and we continued to increase market shares in more markets and category combination than over 55% of our branded sales in retail we see growing market shares. Some of you might remember that this was 70% in the third and fourth quarter of last year. Of course, the massive focus on price increases has some impact here in our negotiations with customers, retailers, and distributors. I think this still shows how strong our brands are and how strong our market positions are, that in spite of the massive price increase pressure that we are applying now, we are still growing market share in 55% of our branded retail sales.
Moving over to our three, not new segments, but it's the first quarter where we report in these three segments, starting with Health & Medical, which showed a very strong organic sales growth of 9.5% coming from volume, prices, and better mix. Actually, we also see significantly high cost for raw material and in distribution, even in Health & Medical, and this applies to the incontinence care healthcare part of the business, where we see very high price increases or cost increases for super absorbents, other oil-based derivatives that we use in our incontinence products. The impact on medical is much smaller, which is of course one of the reasons why we really like this business. We have implemented price increases.
You can see 2.2% of the growth comes from price and mix. This is less than for the other two segments, the reason being that in many cases, we are working with the public sector tender contracts that have a duration of three years, and it takes longer. Also going forward, it will take longer to compensate. We are putting as much effort into price increases in this segment as in the other segments. It takes longer due to the reason I just mentioned. As you can see, organic sales growth both in mature and emerging markets and both in the incontinence products part and the medical solutions parts here. Moving over to Consumer Goods, where we have by far the biggest negative impact from raw materials.
We also see a very strong organic sales growth from higher volumes, higher prices, better mix, and cost savings. In the bars below, again, volume contributes, but even more price and mix, and this has been clearly the priority. As I've stated many times before, we go for pricing even at the expense of volume, and this is clearly also our intent going forward. We see significantly higher costs for raw materials, energy, and distribution in the quarter, and we will also do that going forward. I will give a summary on our outlook in these areas also for the second quarter when we're done with these three segments.
Again, we are working to continue to increase prices so that we have a positive benefit from price and mix also in the coming quarters. Maybe another positive, or not maybe, a very positive sign is that we have positive mix more or less everywhere, which of course indicates that so far we don't see any significant downtrading due to higher prices. On the contrary, we see that consumers actually still prefer premium products and innovation. This could change going forward, but so far we see improving mix in most markets and in most categories. That's very, very positive. Looking down in the right-hand corner, it's quite amazing with the growth numbers here in incontinence products, retail, feminine care over 20%, but also baby care and consumer tissue.
This doesn't include what we think any panic buying. It actually includes quite low growth from China. What I think this shows is how impacted even these categories were during the pandemic and the following lockdowns and restrictions. Maybe we didn't even really realize that. Of course, we see this positive impact now that most markets in the world, except for China, are opening up again. It's a normalization is our interpretation of these strong numbers. Plus, of course, the fact that we are taking a lot of pricing and also mostly gaining market share. Finally, Professional Hygiene, which has by far the highest organic sales growth, at 29.8%, nearly 30%. This was also the segment that was most negatively impacted by lockdowns and restrictions. A very strong rebound.
In this growth, we also have a lot of pricing and also volumes as the adjusted EBITA margin ends up at 7.5%, and this is due to the impact again of raw materials, energy and distribution. Specifically for Professional Hygiene, we have seen that recycled fibers have been going up immensely during the first quarter of this year. We will see how that develops going forward. Again, significant price increases implemented and further increases in the pipeline and planned for the rest of the year. I promise to get back on our outlook when it comes to some of the major costs for the second quarter, and it's the same story as we've had now for a number of quarters.
We expect significantly higher costs for raw materials, all raw materials, maybe with one or two small exceptions, significantly higher energy costs, and also significantly higher transport costs in the second quarter. This is both year-over-year and sequentially. The cost inflation continues. We are showing that we have very, very good momentum in all our categories when it comes to price increases. We remain with the statement that I made at the fourth quarter that we expect to see now gradually increasing margins in the coming quarters. In the second quarter, I would say similar or slightly increasing because of the strong performance we had now in the first quarter.
Still, when we see the pricing that we already have in the books for the second quarter, we feel confident that we will be able to slightly increase margins also in the second quarter, in spite of the headwinds being significantly higher, the cost significantly higher than what we could see when we made this outlook for 2022. That was of course before the war in Ukraine. Summarizing the three segments and then just briefly on 2022 priorities. Price increases, price increases, price increases. Again, there's inflation. This is not going to end in the near term, but our ambition is of course not only to catch up, but also to gradually step by step, starting to see improving margins going forward.
Cost savings continue to really add to the mix, and we have a strong underlying cost savings program that is somewhat now being offset by inflation. The underlying savings are strong. Innovation, digitalization, sustainability, as important as ever. Of course continue to grow in high return businesses and to do with value creating M&A going forward. With that, I'm done with the presentation and let's open up for questions. Thank you.
Open up the telephone lines.
Thank you. If you have a question, please press zero and one of the telephone keypad now to enter the queue. We have a first question. It's from Celine Pannuti of JP Morgan. The line is now open for you.
Thank you. Good morning, everyone. My first question will be on pricing, especially in the Consumer Goods division. It came better than expected. I noted that there was a strong growth, in fact, developed markets in terms of organic growth. My question is, where are we in terms of pricing implementation? Because last time you guided that it will have a gradual impact into Q1. It clearly came much stronger than expected. Are we still expecting a sequential acceleration in Q2? You are talking about next price wave. When will that effectively come into impact? Are we looking at Q3 or later on? My second question is on understanding your guide for margin in Q2. You said gradual improvement.
Maybe it's linked to my first question on pricing, but I was expecting to have much more of a rebound. I was wondering whether it's just because you didn't get all the cost inflation yet in your P&L. Was there some cover that helped you? I know you said significant increase everywhere, but I don't know if you could give us a bit more of a steer on that for the second quarter. Thank you.
Thank you. Fredrik, would you like to talk to that?
Yeah, I can start, Magnus, and please fill in. I think when it comes to your first question, Celine, pricing was strong, as Magnus already alluded to in the first quarter. We do expect actually a sequential acceleration, but that's obviously needed because of your second question. We see significant cost increases, as Magnus already said, in all of our three areas. Has there been a delay? No, not really. We can see that as you obviously know, if we take energy as an example, of course, as we have now kind of continued in time, prices are gradually coming into our cost structure as we move on.
Although we still have a good hedging level for Q2, the prices within those hedges are much, much higher, and particularly so for gas as an example. We also see that, as an example, super absorbents and fluff pulp are increasing very, very significantly and are gradually coming in and increasing. We need that sequential acceleration of pricing to actually compensate for that significantly higher cost that we have in front of us. This is the background to Magnus' comment there that in line or somewhat higher as you said on our expectations for margins.
Just to point out, of course, the obvious uncertainty of the world at this point of time. It is difficult to forecast, but we are still expecting a somewhat higher margin, as Magnus said.
Just to fill in.
Yes.
Celine here, again, we do see accelerating pricing having a positive impact on the second quarter. Of course, we are in preparation and in negotiations with customers everywhere also to have another wave for the third and fourth quarter. This is something that we're in and where we are confident based on the momentum that we're already seeing that we will be able to get additional pricing towards the second half of the year. This is necessary to have sequentially improving margins throughout the year.
Maybe Magnus, just to add what you may have already implied, I guess, but the conviction from our side that margins will come back to the previous where we have been and beyond there, reaching our long-term financial targets, that conviction is still equally strong. This is a matter of time, and we continue our efforts to increase prices accordingly.
My question on the pricing in mature markets in Consumer Goods you had alluded to about mid-single digits. That was what you had been able to negotiate. Now, if I look at the growth rates, like for like, it's close to 14%, so it seems that it was much higher than that, the pricing. Can you comment on this, please?
Fredrik?
Yeah, I'm not sure I understand the question, Celine.
Yeah. I think you did mention in the past that you were able to get a pricing of mid-single digits in tissue Europe. Now things have changed, but your reporting is consumer goods, and the like-for-like in Consumer Goods is 14%. Does it imply that your pricing was much higher than that?
No, not really. I think we
Was there volume there?
Celine, what we said when it comes to consumer tissue specifically, if we just stay on that for a second, then we said that kind of achieved last year was roughly about 5%, so fully implemented, didn't have all that impact of course during Q4, but that was fully implemented at the end of last year. That's what we said. Of course, we have continued to further increase prices. There has been a sequential impact during this quarter, and there will be much further sequential impact as we go now forward when all those price increases are fully implemented. It's not only consumer tissue. We've also raised prices very significantly as an example in feminine, and we've also done it actually for all categories.
I guess we're pleased with the progress, but we will need to continue obviously as you can see.
Thank you.
The next question is by Victoria Nice of SG. The line is now open for you.
Good morning, everyone. Thank you for taking my question. My first question is on the tax rate, which was again much lower than your structural tax rate of 25% in the first quarter. Can you give us some color on what's driving that and whether it has a knock-on effect for the year, meaning tax is likely to be lower than the structural 25% in 2022? Or was it just a timing difference? My second question is on supply chain and whether there's been any demand not met because of supply chain disruption. Also related to that, have you experienced any difficulties getting the energy that you need, or have you received any pressure to reduce the amount of energy you're using at all at the moment, please? Thank you.
Maybe I can start, Fredrik, and I'll leave the tax rate to you. We have not experienced any shortages of energy supplies. But of course, this is something that we are preparing to mitigate for any such risks, taking various measures to ensure that we will have energy supply, especially in Central Europe, also if there would be less access to natural gas. But we haven't seen any issues with that. When it comes to supply chain disruptions, I mean, over the last year, we've had lower service levels than we're usually accustomed to. Still, our customers have been satisfied because we have higher service levels than most competitors. The reason is that the supply chain is operating. We have raw materials. Our staff is working very hard.
It's mostly in, actually, transportation and logistics where there's such a lack of capacity, and this can create delays and disruption sometimes. But overall, our service levels have been better than competition, and actually in this quarter we've seen a slight or quite good improvements in some geographies, specifically in North America. How this will develop going forward is very difficult to say. Tax rates, Fredrik.
Yeah, Victoria, thanks for the question there. Of course, obviously, tax is a full year issue, and for every quarter we adjust for whatever one-time issues that occur during that quarter. The best estimate for our tax rate is of course always the structural, which is roughly about 25%. In this particular quarter we had a one-time issue that affected the tax rate in this specific quarter. The best estimate for the full year is still the structural tax rate, but hopefully what you have seen, the slightly lower tax rate here for Q1 will also trickle down to the full year leading to a slightly lower visible tax rate for the year. It's difficult to say at this point.
The next question is by John Ennis of Goldman Sachs. Your line is now open for you.
Hello, everyone, and thank you for taking my questions. My first is around surcharge pricing. I think you've talked in the past about taking surcharges given the commodity and energy environment. Can you just explain exactly how that works and maybe give us an update on where you are with that strategy? Then my second question is on, I guess price versus mix growth in the quarter. Could you break down the 7% between price and mix, just to give us a sense of the size of the pure pricing that has been taken so far, and maybe call out if that varies materially by any of your product segments? Thank you very much.
If I start with the surcharge pricing, and Fredrik, you talk about price mix and the mix component. Basically we do have energy surcharge pricing on tissue, both consumer tissue and Professional Hygiene tissue in Europe and also coming in the second quarter in North America. And most of this is applied to the second quarter. It's a surcharge, but actually we don't see this any different from a price increase because every price can be renegotiated these days really at any time. We don't have, in the surcharges, really any ways to calculate, you know, when does this go away and what. There's no real link to the natural gas prices or electricity prices and how they develop.
This is a surcharge until further notice. From that perspective, it doesn't differ from how we negotiate and how we talk to our customers in normal price increases.
Yeah, I'll take maybe the second question then, John. Normally we don't expose that split between price and mix, but of course it's quite big this time. We'll provide you with some additional data there. If you take Health & Medical, of the two, just over 2% there, pretty much everything was actually related to price. Mix was low, which is a bit unusual for Health & Medical, but mostly price in that number. When it comes to Consumer Goods, that total number of 8.3%, 7% of that was pure price. If you take finally Professional Hygiene of that 9.5% that you see there in price mix, 7% also for PH was related to pure price.
That's great. Thank you very much. Sorry, Magnus, on the surcharge point, did you say that now, that from a timing perspective is predominantly in 2Q? Is that what you were saying?
That's correct. We include that when we talk about, you know, sequentially.
The sequential improvement in pricing next quarter.
In Q2. That's kind of included in our overall statement of additional pricing coming through in Q2. We don't separate that.
Okay. Understood. Thank you both.
The next question is by Charles Eden of UBS. The line is now open for you.
Hi. Good morning. It's Charles Eden from UBS. Just a couple of questions from me, please. Firstly, could you just talk us through the reason behind the decision to report earlier? Was that driven by Vinda? Was it from your end, given obviously the expectation you were gonna come in ahead of consensus? Just trying to understand the decision behind that quickly. Then secondly, when you look to increase prices through the balance of the year, is the objective to be able to hit your above 17% medium-term ROCE target based on the current market conditions, i.e. raw materials, energy, et cetera? Is that how you view your decision to price?
I'm just trying to get a sense of how that pricing might progress through the rest of 2022 and then into 2023. Linked to that, obviously Vinda reported this morning as well, broadly flat, constant FX sales growth. Is that a market where you do expect a meaningful pricing contribution going forward, given clearly there wasn't a huge pricing benefit in the first quarter? Thank you.
Okay. Yes. The reason to report earlier was really a mix when we saw that there were so many different moving parts, and in combination we had the numbers we decided to report early. As you mentioned, the performance of Vinda very much our decision then to exit Russia and also in general how things were moving in the financials. It was a combination of all this. That's why we decided to come out early. From that perspective, it wasn't one single thing that made us report early. We could combine all these three and other moving parts in our reporting.
When it comes to coming to the 17% medium-term ROCE target, I mean, we assume that we will be able to not only capture it, but then accelerate past the ongoing cost inflation in different areas. Regardless of the underlying cost developments, we just need to raise prices further. We don't expect that by the end of this year, we'll be done with pricing. We see inflation everywhere, and we spoke about this over a year ago that this was to be expected, so we just need to continue to raise prices and trust our strong brands and our strong market positions faster than the underlying costs and, through that, to see gradually improving margins. That's how we view it.
It's not that we're waiting. I guess that's what you're implying for raw materials or anything to come down. I mean, if that happens, I mean, of course, that would help, but that's not what we're assuming here. We will continue to raise prices continuously as we've done over the last year, and we see increasing momentum and opportunities for that, going forward. Vinda had more or less a flat first quarter. Vinda is very, very strong in the tier one cities and on the coast, and it's mostly these cities that have been in really, really tough lockdowns. Even though our plants are actually fully operating in China, we have been unable to deliver, for instance, to Shanghai, to some extent in Hong Kong and in other major cities.
This has had a major negative impact on sales, and let's see how this develops in the second quarter if there will be some easing of these significant lockdowns. Vinda is working also with price increases. They will also face increasing raw material costs in the second quarter, so this is an important part of their strategy, just like for the rest of the group. Fredrik, do you want to add something?
Yeah, maybe I think you probably already said it, Magnus, but Charles, just one maybe reminder going back a bit. When we set that long-term financial target for 2025, more than 17%, we didn't base it on any pricing. There were no pricing assumptions in there. It was basically flat. The assumption was that we were, or actually we were at the time, and we still are heading for an improvement of our structural margins. Of course, that improvement was supposed to come and actually still is coming from things that you already know. Things like innovation, efficiency gains, growth in high-yielding areas, digital and many other things that you're aware of. That structural improvement, although it may be really difficult to see now, is still going on.
This, the second assumption that we had at the time was always that we can always compensate the cost potential cost increases or cost inflation through price, and that remains our assumption, as we alluded to earlier. We think that we have kind of time in the timeframe we're talking about here, that's for sure enough to compensate the pricing necessary to compensate for the inflation. The improvement is structural, and that is, as Magnus said before in his presentation on the final slide there, it's still ongoing. We're working with our structural improvement, although that may be difficult to see in the midst of everything else, but it's still structurally improving.
I mean, just number-wise, I mean, it's improving maybe 0.5% to 1% to 1.5% per year. It's when we have cost headwinds of 12% over a year, again, it kind of doesn't show. The cost increases in raw materials, the transportation energy, that we compensate with pricing. Yeah, just to underline.
That's great. Thank you very much.
The next question is by Fulvio Cazzol of Berenberg. The line is now open for you.
Yes. Good morning, and thank you for taking my questions. I've got three. The first one is on Russia, whether you expect a potential disruption on supply chains, for example, industry pulp. If you could comment on that. Then sticking with industry, could you give us an update on the general industry capacity situation in Europe? I know it was tight, and you've indicated that in the past, but I was just wondering, are you seeing any signs of players reentering the market now that industry pricing is starting to gather some momentum there? Then my last question is on hedging.
Given where, you know, commodity prices are now and also energy prices, you know, how are you thinking about re-hedging as the hedges run off, you know, in the coming periods? Will you be looking to maintain similar hedging to what you've had in the past, or could you be a little bit more strategic and maybe, you know, be a little bit less, you know, focused on hedging levels, in preparation for when eventually these will ease again? Thank you.
Okay. I start with the first topic, Russia. Of course, we follow very closely all the evolving legislation, both in Europe and inside Russia, and follow all legislation very precisely. I think that's important to state first of all. This means that when it comes to the personal care part of our Russian business, we have been gradually ramping down since that part of the business has been dependent on importing some of the oil-based raw materials, and that's not possible. We are not shipping any finished products or raw materials over the border to or from Russia. The tissue business is operating, and it's based on the Russian raw materials entirely. It's like a separate island organization and setup, and also in local currency.
That continues to operate. We will now, you know, over the next period, see how we can exit that business. It's still operating. The employees are working, and of course, we are paying the salaries and running the business. We want to do this in a responsible way over the next time period. Industry capacity, I'm not sure I understood the question, so please, if I got it wrong. What we have seen, actually in the first quarter is that, for a few days here and there, when natural gas prices spiked, quite some of the tissue capacity in Europe was shut down, due to the high cost of operating. This was not the case for us.
We are hedged, as we mentioned many times, and we also have a very, very good cost position. This has been to the benefit of Essity that we've been able to continue to run and deliver to our customers, and of course, very much appreciated by our customers also. During the last couple of years, we haven't seen much new capacity coming in in either tissue or in personal care in Europe or in other markets because of the pandemic and now, of course, the recent volatility.
Yeah, Fulvio, maybe I should take the third question there.
Yes.
You were asking about the hedging. We don't really hedge raw material. We hedge energy, as we've said a couple of times. The way that works is that we have a three-year horizon. The first year is normally quite hedged, and the second a bit less, and the third to a much lesser extent. That's how it works. It's a band, so there's a maximum and there is a minimum that we can operate within, in all, for all those three years. There is a bit of flexibility within that policy, and of course, especially in the outer years, so in kinda year two and three.
I think it may be the case that we will be somewhat strategic in the sense that we will be in the lower band of that hedging or, yeah, allowed hedging level. That's more a strategic decision that we'll continue to come back on. It's more a continuous management, you can say.
Great. Thanks. Thanks for that.
The next question is by Oskar Lindström of Danske Bank. The line is now open for you.
Yes. Hello. Thank you. This is Oskar Lindström at Danske Bank. A couple of questions from me. First one just on your comments about margins in Q2. You said both similar or slightly higher, and then I think later on you said only slightly higher. I mean, what's your conviction on the margins for Q2 versus Q1? That's my first question. My second question is on Russia again. How much, you know, of your Russian sales was how much of your sales were lost in Russia in this quarter? You know, what was the impact on organic growth, basically, year-on-year? And what should we expect for the coming quarters? And also, what was the margin in Russia below or above the group average?
My third question is on A&P and SG&A development. I mean, given that we're now seeing quite high sales increases due to price increases, which are driven by raw materials, should we expect the share of sales of both of these to come down? Those are my three questions.
Okay. To the first question, I can only say that, I answered an earlier question about the reason to report early, and one is that there are so many moving parts now, Oskar, and, I mean, I think we saw very, very strong pricing, but also throughout this quarter, even higher raw material transport and energy costs. There are so many moving parts, and that's why I mentioned it the way I did. We can't be more specific like that. There are so many different parts. We know that we have a lot of pricing coming in the second quarter, but also a lot of additional costs, basically. Can't be more precise than that.
I think I'd hand over to you. When it comes to Russia, of course, the margins we never comment on, but when it comes to sales in the first quarter, how did that look, Fredrik?
Oskar, we never comment on individual countries here, but it's from an organic growth perspective, it was not material for the group in any way. The difference in sales in Russia was not material for the group.
Just G&A and A&P.
Yeah. I think, I mean, with... You've seen it here, Oskar, that as a percentage of sales, it has come down, and it's of course on the back of that strong organic sales growth. I think we have iterated many times that our efforts when it comes to building our brands and to marketing our innovations and launches remain on a good level. Of course, we will continue and on an absolute level to have those investments going forward. When organic sales growth goes up like this, it's natural that we'll see a bit of decrease when it comes to the percentage of sales.
All right. Thank you. Just if I may follow up, you, Magnus, on the first question there. I mean, coming back to your price increases and, your, you know, customers' acceptance for price increases that you've been pushing more aggressively lately, have you been positively surprised by your ability to push through price increases?
Yeah, momentum is increasing continuously. When we started talking price increases in April last year, there was a lot of pushback and maybe also not much momentum. We couldn't see that this was a strong trend in many countries or categories. Then gradually, of course, and especially towards the end of the fourth quarter when costs really took off, I think both our customers and competitors woke up kind of and saw what was coming. This continues now throughout 2022. There is an increasing acceptance for continuous price negotiations and continuous price increases. We see that with the current situation.
As I referred to, for instance, when it came to the natural gas situation just a few weeks ago, this is something that everybody needs now and everybody's pursuing. Momentum has continuously improved for price increases.
All right. Thank you.
This is in all categories, and where it's still very challenging is where we have the three-year contracts with the public sector in Health & Medical. Also there, as you can see, in spite of that, we had 2.2%, which is quite a lot, but not sufficient. We continue our efforts there as well.
Thank you.
The next question is by Linus Larsson of SEB. The line is now open for you.
Thank you very much, and good day to everyone. On surcharge pricing, I wonder, is that exclusively targeting energy cost inflation? On that topic, is the current market such that you can fully offset energy cost inflation as we go, i.e., shouldn't we worry too much about the energy part of cost inflation going forward?
It's not that sophisticated because then it becomes very complex, especially with the swings now in the energy markets. The surcharge, yes. What we call surcharges are entirely related to energy, but it's typically a fixed percentage on whatever pricing that we have, which is and reflecting what we believe then will be the energy price development. It's not that sophisticated. Again, I would like you to see it as part of our overall pricing effort.
I would like to think that maybe some of your competitors are struggling more than yourselves, and for that reason, the acceptance for that type of price additions should be, you know, even higher than has been.
It's something that our customers understand. They can read about electricity and natural gas prices. Our competitors are in many cases, as I refer to, have been suffering more than we. From that perspective, it's very, very decent.
Okay, cool. Just on Russia, you express an intention to exit Russia altogether. Just to be clear, could you maybe say what's driving that decision? Is it the overall operating environment? Is it, you know, potential breach of sanctions or is it something else?
It's business related. The business conditions that are deteriorating.
That's clear. Thank you very much.
The next question is by Tom Sykes of Deutsche Bank. The line is now open for you.
Morning, everybody. Just firstly, on the price effects, is that all list price, or is there an effect of lower promotions in that? What do you expect to happen to promotions over the course of the year? Will those go up at all? I'm just interested in your comments on market share, where you think you've taken or lost the most market share, please. Just related to the previous caller, your sales increases are highest in private label in consumer. Do you have any comments on your volume share, say, within consumer of the branded versus private label there, please? Finally, are there any areas where there's a restocking benefit, where there was a COVID related to the reopening benefit? You know, thinking about professional in particular, please.
Yes. I will start, and then Fredrik will fill in. When it comes to restocking, it's nothing that we have really seen or heard. I mean, there could be some of that, but not to any significant amount. Private label consumer tissue is increasing. A lot of that is price, of course. This is where we have the biggest need of price increases and where we've been most aggressive. In spite of this, we have had some customers coming back to us because of the reason I mentioned that we lost a lot of volume last year when we started increasing prices more than anybody else. Now some of those other suppliers haven't been able to deliver actually. Those customers have come back to us. That's the dynamic there.
That could change again, of course. That's why this part of the business is more volatile. We are very aggressively, I would say, pursuing pricing in private label tissue in Europe, and that's visible in the numbers. Market share, it's not really that we're losing market share now in many areas, but we're not growing to 70% as we did before. I would say it's either growing or stable, and it's the same areas as before in Feminine Care, in Incontinence Care, we are doing well, especially in Incontinence Care Health Care. We think we're growing share in Medical. This is, of course, we don't have Kantar data, but this is what we're seeing. We're doing really well. In Professional Hygiene, same thing.
We feel that we are gaining market share without Kantar data. In the retail parts, in consumer tissue, even though we are raising prices, because of our high service levels and quality, we are still retaining the customers. Please help them fill in here, Fredrik.
No, I think, maybe on the first question there, I think your question was on the price, whether that's list price or whether it's promotion.
Mm-hmm.
The absolute dominating part, Tom, is relating to price, pure price increases. Promotional levels, at least parts of our operation or parts of our business is slightly lower. There is a positive impact also for that. In general, it's mostly pure list prices.
Okay, thank you.
The next question is by Iain Simpson of Barclays. The line is now open for you.
Thank you very much. I just, you gave us some color on the energy hedging, which was very helpful. I wondered if you could give us any sense as to how quickly the sort of unhedged element of your energy costs kind of flow through from wholesale price movements to your own P&L. I know that in some places you operate in regulated markets. Secondly, apologies, I missed the very start of the call, so sorry if this has already been asked. Could you talk a little bit about your logistics arrangements? How much of your logistics and distribution do you sort of do in-house with, you know, your own trucks and your own permanent staff, versus how much is outsourced to third-party haulage companies?
I'm just trying to get a little bit of a sense as to how the mechanics of your distribution costs might unfold this year. Thank you so much.
Okay. Now I'm staying with this backward policy of answering the last question first and giving the first question to Fredrik. Anyway, no one asked about the transport and logistics, but it's a good question. It's a very challenging area. We don't own or operate any logistics. We don't have any trucks or any drivers or any sea freight, so this is something that we're buying. Having said that, we have huge benefits from the digitalization work we've done over the last three, four years in this area. We have a central global transport hub in Barcelona where we are then working with hundreds and hundreds of suppliers, distribution companies, and market warehouses and so on, and optimizing.
Because of this, we get scale, so we become more relevant, but it also makes us more efficient on the spot market, which we have been working with more than before because of the scarcity of capacity. So thanks to having actually a global overview of transportation distribution flows with the exception of Latin America so far, it's really helping us to get products out to our customers. But we don't do any of that ourselves. Over to you, Fredrik.
Ian, maybe a bit of background. Let's take Q2 then as an example. When it comes to gas, natural gas, we've hedged roughly about 75% of our consumption for Q2, and then it goes down thereafter for the following quarters and following years, of course. When it comes to electricity, about 37% of our electricity purchases are hedged. To that number, you need to add the regulated markets which we operate, and they represent approximately about 30% of our purchases. If you add that up, roughly 67% or, yeah, close to 70% of our energy hedging in Q2 is hedged and thereafter also reducing. That's roughly what it looks like.
Your question was on how fast the flow-through is of the non-hedged when it comes to, I take it, electricity, and that's more or less immediate or very, very fast. It also goes actually for gas, so for the non-hedged part.
Thank you very much.
The next question is by Eva Quiroga. The line is now open for you.
Yes. Good morning. Two questions, please. Can you highlight what the price component has been in developed versus emerging markets, and maybe directionally talk a little bit about the margin development in these two regions? My second question is coming back to the private label question. Am I right in understanding that the big growth you've had was partly regaining contracts and pricing rather than there being any evidence of consumers trading down? I think earlier in the call, you've talked about people looking at premiumizing. Can you maybe just elaborate a little bit on that?
Again, second question, it's as you say, we don't see downtrading yet. We're preparing for this, of course, with a good better best assortment and having something for different pack sizes and so on. We haven't seen that yet. We think that this is volumes that we're getting back that we lost, and we can see that, and pricing. When it comes to the price mix component between developed and emerging markets, Fredrik.
Yeah, maybe a bit, Eva, a general comment. It's a bit of mixed picture because generally, I think we've said this many times, but the flexibility or adaptability in emerging markets when it comes to Latin America is fairly fast. We have a very, very good pricing environment when it comes to Latin America. In particular so when you look at the family numbers as an example. We have good volume growth and pricing in that field, as an example, in Latin America. When it comes to China, as we've already talked about, less aggressive on pricing there. There has been pricing, but of course, not as much.
Generally, I think it's been a good pricing environment in emerging markets, but with some variations.
Operator.
The next question is by Jeremy Fialko of HSBC. The line is now open for you.
Hi. Morning. Jeremy Fialko, HSBC here. I've got some more questions on margins looking forward. Now, clearly you've been quite helpful in terms of the sort of Q2 margin guide. If we look over the balance of the year, there's a couple of questions related to that. Firstly, would you characterize the margin build, as you say, go Q2, Q3, Q4, as being a kind of a gradual improvement, or would you look to see a kind of a bigger step up as you get into the second half of the year?
The second question related to that is, certainly when I look at the consensus that was published yesterday, you know, the analysts, you know, on average have got you exiting the year at a, you know, sort of low double-digit adjusted EBITA margin, so that would be kind of the Q3, Q4 level. Do you think that is realistic? Given what you can see in terms of your kind of volume, the price rise you've got agreed. But then at the same time, some of the incremental costs that will come in as, for example, your hedges roll off, but you're kind of, you know, you're getting stuff at the near of what current spot prices are versus what you previously hedged. So a little bit more color on that would be very helpful. Thanks.
Again, as I answered before, and I think you covered it quite well, there are so many moving parts. It's impossible to say, and of course, we don't make forecasts. I did give a little bit of guidance during Q4 for Q1 as during Q4, just to kind of correct the overall picture, and that was before the war. Since then we have the war, of course, again, leading to even higher costs in all areas. I mean, right now, the only thing I can say, we're not seeing that any costs would come down in the second half of the year. I can't say that we're seeing any signs that they would significantly go up either.
What we can say is exactly what we stated, that for the second quarter, we will have significantly higher costs in almost all areas. So that's basically it. We don't give an outlook for the longer term on margins. So I think that's what I can say on this area.
Okay. If that's all the color you can give. Thank you.
Mm-hmm. Let's see here. It's a couple of minutes past ten, Joséphine. I don't know, should we take one more question?
Yes. Operator, do we have any more questions?
There are no further questions at this time.
Yeah.
Maybe I could make a short summary, Joséphine.
Yes. I was just gonna say, if there are no more questions, then why don't you make a concluding speech?
Thank you. We're living in very difficult times and the war in Ukraine was of course something for most completely unexpected and the consequences and it's actually terrible times. We are very focused on our employees in Ukraine and our employees throughout the world and of course also in Russia. We are providing tons and tons of our products to refugees in neighboring countries. We are providing significant amounts of wound care products to Ukraine and other types of products. Our staff, about 70 employees in Ukraine, they are working very diligently to continue to supply our product in Ukraine, which is fantastic.
Of course, this is something completely different than when we met, presenting the fourth quarter of last year. The impact on global markets, I think we have talked about many, many times now. What I want to kind of emphasis coming out of this is, of course, the very unfortunate decision to pull out of Russia. Again, we will do this in a responsible way and with the best interest of our employees in Russia, also, in mind. The other one is that I think we have really been able to prove the strength of our brands and our market positions in pricing power. We will see sequentially even more pricing in the second quarter, and we're preparing even more pricing for the quarters to come.
That's very, very encouraging going forward. We see now that there is the momentum and our organizations, our customers, our consumers are also accepting higher pricing to compensate for the cost increases. That's very, very encouraging in a very, very difficult time. I guess that's my summarizing remarks. Thank you all for calling in and for listening.
Thank you, Magnus, and thank you, everybody, and thanks for calling in. Have a good day.